AZD7762

Name: AZD7762
Brand: Selleck Chemicals
SKU: S1532
Rating: 5 (68 reviews)

For research use only.

Catalog No.S1532

68 publications

Molecular Weight(MW): 362.42

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Selleck's AZD7762 has been cited by 68 publications

Cancer Cell, 2019, 35(6):851-867

PubMed: 31185210 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2012, 2(6):524-39

PubMed: 22628408 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Biomaterials, 2020, 248:120032

PubMed: 32304937 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2416-2429

PubMed: 32075739 ( click the link to review the publication )

Haematologica, 2020, 105(3):784-795

PubMed: 31289205 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1300-x

PubMed: 32335582 ( click the link to review the publication )

Cell Death Dis, 2020, 28;11(4):298

PubMed: 32345958 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):1726

PubMed: 32610557 ( click the link to review the publication )

Life Sci Alliance, 2020, 3(8):e202000671

PubMed: 32571801 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1032-1045

PubMed: 30771522 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cancers (Basel), 2019, 11(8)

PubMed: 31362447 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):762-770

PubMed: 30872379 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )
Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:195

PubMed: 31372095 ( click the link to review the publication )

Cell Cycle, 2019, 18(8):834-847

PubMed: 30943845 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14916

PubMed: 31670839 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0290

PubMed: 31871265 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1629-1643

PubMed: 29326282 ( click the link to review the publication )

Diabetes, 2018, 67(11):2319-2328

PubMed: 30104248 ( click the link to review the publication )

Cancer Lett, 2018, 431:142-149

PubMed: 29859297 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1392

PubMed: 29123096 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cancer Lett, 2017, 392:71-82

PubMed: 28126323 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):1

PubMed: 28049532 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10966-10979

PubMed: 28030798 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Oncogene, 2016, 35(36):4689-97

PubMed: 26804177 ( click the link to review the publication )

PLoS Pathog, 2016, 12(2):e1005424

PubMed: 26891221 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

J Biol Chem, 2016, 291(17):9330-42

PubMed: 26940878 ( click the link to review the publication )

Anticancer Res, 2016, 36(6):2649-57

PubMed: 27272773 ( click the link to review the publication )

J Pathol, 2015, 10.1002/path.4528

PubMed: 25757065 ( click the link to review the publication )
Biochem Pharmacol, 2015, 93(2):210-20

PubMed: 25478729 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129090

PubMed: 26046346 ( click the link to review the publication )

Oncotarget, 2015, 6(35):37229-40

PubMed: 26439697 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1223

PubMed: 24810059 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Int J Oncol, 2014, 45(3):1159-66

PubMed: 24969815 ( click the link to review the publication )

Int J Gynecol Cancer, 2014, 24(5):838-43

PubMed: 24804869 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

J Cell Mol Med, 2013, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55493

PubMed: 23405159 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Targets

Chk1 ^[1] (Cell-free assay)	Chk2 ^[1] (Cell-free assay)
5 nM	<10 nM

In vitro

AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and K_i of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. ^[1] AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KASUMI-1	NIG0UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvuWWpPUUN3ME2wMlAxODJ\|NDFOwG0>	NXHJV5BDW0GQR1XS
NKM-1	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml6wTWM2OD1yLkCwNFQyPSEQvF2=	MXHTRW5ITVJ?
MV-4-11	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{ex[WlEPTB;MD6wNFA1OjVizszN	NWrUVVhIW0GQR1XS
NCI-H1703	M37wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1izdWlEPTB;MD6wNFY1OyEQvF2=	NVjtcnNXW0GQR1XS
A204	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojETWM2OD1yLkCwPFU3KM7:TR?=	M3eyTHNCVkeHUh?=
CGTH-W-1	NGXtO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDW[WVWUUN3ME2wMlAyPDJizszN	M{jVS3NCVkeHUh?=
MLMA	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEK4OFkh\|ryP	MkfaV2FPT0WU
GOTO	MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLkTWM2OD1yLkCzNVIh\|ryP	M{fJe3NCVkeHUh?=
KE-37	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO5TWM2OD1yLkCzNVQzKM7:TR?=	M1nvenNCVkeHUh?=
ES4	NITPZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTEc3VtUUN3ME2wMlA{OjVzIN88US=>	NX7xNIlkW0GQR1XS
ATN-1	NIXkNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjtVm55UUN3ME2wMlA{PDF5IN88US=>	MoLnV2FPT0WU
MHH-PREB-1	NGXKd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEO0OFIh\|ryP	MVfTRW5ITVJ?
SW756	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u1eGlEPTB;MD6wN\|U4QSEQvF2=	MVTTRW5ITVJ?
CTV-1	M3OwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\JSJpKSzVyPUCuNFM5QTZizszN	NVPB[4N2W0GQR1XS
HCC1806	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLGTWM2OD1yLkC0NFIzKM7:TR?=	M37ySHNCVkeHUh?=
NEC8	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEmwR4hKSzVyPUCuNFQzODNizszN	M1j5SnNCVkeHUh?=
P12-ICHIKAWA	NITTdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrBPJBKSzVyPUCuNFQ{OTZizszN	MUfTRW5ITVJ?
DEL	NWTEdmFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrOTWM2OD1yLkC0OVkzKM7:TR?=	NXLOfWpsW0GQR1XS
KM12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e1TGlEPTB;MD6wOVE2QCEQvF2=	NEXOOJdUSU6JRWK=
LB1047-RCC	NXXJdm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVT0b5lmUUN3ME2wMlA3ODJ3IN88US=>	NGrJU3BUSU6JRWK=
LB2241-RCC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPveHdKSzVyPUCuNFYyODJizszN	Ml\aV2FPT0WU
NOMO-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwME[xNVUh\|ryP	MUjTRW5ITVJ?
NB14	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG2SmtKSzVyPUCuNFYyOzZizszN	MVPTRW5ITVJ?
ONS-76	NEKxWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nGd2lEPTB;MD6wOlE6PiEQvF2=	M3;5[nNCVkeHUh?=
HD-MY-Z	M3\vOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnoN\|NKUUN3ME2wMlA3OjV3IN88US=>	NIjucGVUSU6JRWK=
G-402	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;LVYRKSzVyPUCuNFY1PiEQvF2=	MYLTRW5ITVJ?
ES1	NXX6co9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjnV2dKSzVyPUCuNFcyPDZizszN	NUTJdYQ5W0GQR1XS
L-363	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Oze2lEPTB;MD6wO\|M6KM7:TR?=	MXrTRW5ITVJ?
A4-Fuk	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XwNWlEPTB;MD6wO\|Q5PiEQvF2=	MmDwV2FPT0WU
OC-314	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonrTWM2OD1yLkC3PFA4KM7:TR?=	NXjYXGlPW0GQR1XS
SK-LU-1	NXu1RYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17YbmlEPTB;MD6wPFQzOSEQvF2=	MlHyV2FPT0WU
MDA-MB-157	NEDZcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEi2OVkh\|ryP	NV21XYFqW0GQR1XS
HuP-T3	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3WR2tLUUN3ME2wMlA5PzFizszN	MVnTRW5ITVJ?
A3-KAW	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEi4NFYh\|ryP	NUfh[Vd2W0GQR1XS
MOLT-16	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;UWIhKSzVyPUCuNFg5ODdizszN	MUjTRW5ITVJ?
COLO-679	NXTnbG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEmwPVEh\|ryP	MXvTRW5ITVJ?
EM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3YPZJEUUN3ME2wMlA6QTB\|IN88US=>	MmK1V2FPT0WU
ES8	NEnWU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEm5NVgh\|ryP	NVfqdmc3W0GQR1XS
SK-MEL-2	M4Pzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2qwTGlEPTB;MD6xNFA{OyEQvF2=	NYr3NGN7W0GQR1XS
ES3	M4C2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnk[5JQUUN3ME2wMlExOiEQvF2=	M{HOO3NCVkeHUh?=
HSC-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnwTndKSzVyPUCuNVA2PTRizszN	NUfT[XB6W0GQR1XS
697	M4XGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXqNJRKSzVyPUCuNVExPjNizszN	MonlV2FPT0WU
TGBC11TKB	NUXZfoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmqwTWM2OD1yLkGxNFk{KM7:TR?=	M2C1cnNCVkeHUh?=
SK-PN-DW	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWezOGNSUUN3ME2wMlEyQDZizszN	NEnHRpNUSU6JRWK=
H9	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHZS45LUUN3ME2wMlEzOTZ3IN88US=>	MX;TRW5ITVJ?
NCI-H2122	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHFOnNKSzVyPUCuNVIzPSEQvF2=	MlTIV2FPT0WU
ML-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofTTWM2OD1yLkGyOFg1KM7:TR?=	MnHLV2FPT0WU
MC-IXC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnyOGpKSzVyPUCuNVI5PDNizszN	NXTlR5pDW0GQR1XS
KYSE-140	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP2bohKSzVyPUCuNVMxPDFizszN	MmjCV2FPT0WU
DOHH-2	NUL1OpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3YblJKSzVyPUCuNVMxPjRizszN	NXPoZpV6W0GQR1XS
MEL-JUSO	NWK0fYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUOxNlgh\|ryP	Ml7SV2FPT0WU
P30-OHK	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\VTohKSzVyPUCuNVMyPiEQvF2=	NW[zfpRXW0GQR1XS
CTB-1	NGT0T3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMUOzNlUh\|ryP	M3XHdXNCVkeHUh?=
ACHN	NUKzU\|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DL[GlEPTB;MD6xN\|M3QSEQvF2=	MXzTRW5ITVJ?
ES5	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e3RWlEPTB;MD6xN\|Q4PiEQvF2=	NXXFfoUxW0GQR1XS
SF539	NH;IS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfwNVlDUUN3ME2wMlE{PjhizszN	NVjaVW5OW0GQR1XS
D-283MED	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXvTWM2OD1yLkGzOlg4KM7:TR?=	MXfTRW5ITVJ?
OVCAR-5	NV;ufnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfqTWM2OD1yLkGzPFk1KM7:TR?=	M2rnVXNCVkeHUh?=
RPMI-8866	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTacYpKSzVyPUCuNVM6OjVizszN	MlTFV2FPT0WU
PANC-03-27	NXe1e2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnUfIpGUUN3ME2wMlE1Ojh6IN88US=>	NXLy[3V4W0GQR1XS
M14	NY[2OWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7RRVZiUUN3ME2wMlE1PDZ\|IN88US=>	M{m3fXNCVkeHUh?=
D-566MG	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;4eGlEPTB;MD6xOFY6KM7:TR?=	M3HoTXNCVkeHUh?=
Ramos-2G6-4C10	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rnR2lEPTB;MD6xOFg1OiEQvF2=	M1;2T3NCVkeHUh?=
NOS-1	M2jJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDkTWM2OD1yLkG0PVY4KM7:TR?=	NWr4cG1HW0GQR1XS
YH-13	NIPCO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7hWlA5UUN3ME2wMlE2Pjd2IN88US=>	NFHQUXNUSU6JRWK=
NB17	NVmy[pFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHoZY1KUUN3ME2wMlE2Pzh4IN88US=>	Ml;sV2FPT0WU
U-2-OS	NW\FeWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfCbnJKSzVyPUCuNVU5PDdizszN	NILqZpBUSU6JRWK=
ES7	NILSTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vsRWlEPTB;MD6xOlAyOSEQvF2=	MVjTRW5ITVJ?
LoVo	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMU[xOlYh\|ryP	NV;2VIg2W0GQR1XS
QIMR-WIL	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMU[zNVEh\|ryP	MYXTRW5ITVJ?
ESS-1	NEPzcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMU[0NVMh\|ryP	MUTTRW5ITVJ?
LAMA-84	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrkTWM2OD1yLkG2OVA{KM7:TR?=	NFzFVmtUSU6JRWK=
TGBC24TKB	NEnnVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPEVWlKSzVyPUCuNVY2OzVizszN	NGrUR\|hUSU6JRWK=
KU812	NIfmRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMU[4N{DPxE1?	NVj1e3liW0GQR1XS
KARPAS-45	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn6xTWM2OD1yLkG2PFQ4KM7:TR?=	NUPSfHc1W0GQR1XS
ACN	NUXyW5dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXmTWM2OD1yLkG3NVcyKM7:TR?=	MmPvV2FPT0WU
RPMI-8226	M1L3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTkTWM2OD1yLkG3OFY1KM7:TR?=	NHHmPINUSU6JRWK=
GR-ST	NY\IWIplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHjdI9PUUN3ME2wMlE4QDJ5IN88US=>	MV\TRW5ITVJ?
SK-UT-1	NWjlSWJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMUi1PVkh\|ryP	MoDYV2FPT0WU
SK-N-AS	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjMTWM2OD1yLkG4PFE2KM7:TR?=	NGfwOlVUSU6JRWK=
EW-1	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ewVGlEPTB;MD6xPFkxPSEQvF2=	NF7QephUSU6JRWK=
5637	NFO4RWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G5emlEPTB;MD6xPVI4QCEQvF2=	MmC2V2FPT0WU
GI-1	NFftToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon3TWM2OD1yLkG5OVYyKM7:TR?=	MXjTRW5ITVJ?
NCI-H1395	NELPdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnkWGxKSzVyPUCuNVk4PjFizszN	NILYW2RUSU6JRWK=
CHP-212	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XP[WlEPTB;MD6xPVc5OiEQvF2=	MoDnV2FPT0WU
A427	NH;PN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjxc3RKSzVyPUCuNVk5OzJizszN	M1rTO3NCVkeHUh?=
BE-13	NVXUcpZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPsVmw5UUN3ME2wMlIxOTF5IN88US=>	NYq0T5p6W0GQR1XS
RS4-11	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\OO5dKSzVyPUCuNlA{OThizszN	NUT0VJNXW0GQR1XS
TI-73	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33z[2lEPTB;MD6yNFg4OyEQvF2=	NGjMcGJUSU6JRWK=
HAL-01	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfjTWM2OD1yLkKwPVch\|ryP	MUfTRW5ITVJ?
KY821	NEHNRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrQTWM2OD1yLkKxOFI6KM7:TR?=	MYTTRW5ITVJ?
H4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHiZWNKSzVyPUCuNlIxPjJizszN	M3\WZ3NCVkeHUh?=
EPLC-272H	NH3uTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnNbFNKSzVyPUCuNlIxPjhizszN	MVfTRW5ITVJ?
COR-L105	NYr4cFFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMkKyN\|Uh\|ryP	NFHPV21USU6JRWK=
769-P	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LWWGlEPTB;MD6yNlI6QCEQvF2=	NEjvVFJUSU6JRWK=
HEL	NXnCZVMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMkK0OVQh\|ryP	NYDZRoNvW0GQR1XS
VA-ES-BJ	NF3rPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j6SWlEPTB;MD6yNlU2PyEQvF2=	NX7lZY43W0GQR1XS
IST-MEL1	NGXFSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnzb3RKSzVyPUCuNlI2PyEQvF2=	M3iw[XNCVkeHUh?=
KYSE-270	M2TZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMkK2N\|Mh\|ryP	M4jJXnNCVkeHUh?=
RH-1	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVqyfI9YUUN3ME2wMlIzPjZ4IN88US=>	Mo\SV2FPT0WU
JVM-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMkOwN\|Yh\|ryP	M2TXUnNCVkeHUh?=
RPMI-7951	NUC5U2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\RR\|Y4UUN3ME2wMlI{ODV4IN88US=>	MmezV2FPT0WU
JAR	NXvvO\|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PZU2lEPTB;MD6yN\|I{QCEQvF2=	Moi1V2FPT0WU
MOLT-4	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMkO4OUDPxE1?	M{XNWXNCVkeHUh?=
ALL-PO	MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3aTWM2OD1yLkK0NlQ{KM7:TR?=	NGjm[I1USU6JRWK=
SNU-387	M{S4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm2NIZKSzVyPUCuNlQ{OzlizszN	NHX1b4pUSU6JRWK=
IGROV-1	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G4SmlEPTB;MD6yOFQxOSEQvF2=	NV\KW3lJW0GQR1XS
MPP-89	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;XRm9HUUN3ME2wMlI1PDVzIN88US=>	NFSwZYlUSU6JRWK=
T98G	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljLTWM2OD1yLkK0OVY5KM7:TR?=	MWDTRW5ITVJ?
NCI-H510A	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz4c5pKSzVyPUCuNlQ3OjZizszN	M4jxTnNCVkeHUh?=
KOSC-2	NGi0dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMkS2O\|Eh\|ryP	NVjIN3lTW0GQR1XS
NCI-H23	NV\kVHFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HxN2lEPTB;MD6yOFc3OSEQvF2=	NYnSdG9oW0GQR1XS
MC116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:2NmlEPTB;MD6yOVY2PCEQvF2=	M1HlW3NCVkeHUh?=
8-MG-BA	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\3TGlEPTB;MD6yOVc3QCEQvF2=	MYjTRW5ITVJ?
ABC-1	NVTQdmVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\X[5hKSzVyPUCuNlYxPjRizszN	NYHNTnZRW0GQR1XS
J-RT3-T3-5	NGnH[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO3OJdKSzVyPUCuNlY3PzhizszN	M{TocHNCVkeHUh?=
NCI-SNU-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnaTWM2OD1yLkK3NFU6KM7:TR?=	NX76XWtqW0GQR1XS
HCC1395	M3;pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1KxOmlEPTB;MD6yO\|A5QSEQvF2=	M{\QS3NCVkeHUh?=
BB65-RCC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDqZZhSUUN3ME2wMlI4ODl5IN88US=>	NXy5TVNYW0GQR1XS
NCI-H1755	NXfhe5dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLW[lFKSzVyPUCuNlc{ODRizszN	NHvGU\|NUSU6JRWK=
OVCAR-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMkezPFUh\|ryP	NHLkbWxUSU6JRWK=
MKN45	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMke5PEDPxE1?	MoLiV2FPT0WU
TYK-nu	NWr4RoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrqOmpSUUN3ME2wMlI5ODZizszN	NHXCXWVUSU6JRWK=
SNU-C2B	NETu[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnz2TWM2OD1yLkK4NVM1KM7:TR?=	NELtTZdUSU6JRWK=
H-EMC-SS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLiTWM2OD1yLkK4N\|U1KM7:TR?=	NXvkOIp3W0GQR1XS
CAKI-1	M3;iWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moj1TWM2OD1yLkK4Olgh\|ryP	MV3TRW5ITVJ?
EW-24	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmraTWM2OD1yLkK4PVEh\|ryP	NIHtVXVUSU6JRWK=
RXF393	NGj2cnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWm5TIN{UUN3ME2wMlI6ODB6IN88US=>	NUjPcGF6W0GQR1XS
CCRF-CEM	NWXHVmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3izeWlEPTB;MD6yPVE2PCEQvF2=	M3\OOXNCVkeHUh?=
HOP-92	NF3vNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fiSGlEPTB;MD6yPVI4QSEQvF2=	NXLvWJR3W0GQR1XS
COLO-684	NEXMdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1myUmlEPTB;MD6yPVQxPiEQvF2=	NYXOOHd3W0GQR1XS
NCI-H28	M3i1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzpOpNKSzVyPUCuNlk4ODRizszN	M4nzTnNCVkeHUh?=
HuO9	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXH[Vl{UUN3ME2wMlI6Pzl\|IN88US=>	MmPzV2FPT0WU
SF295	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDYPWRKSzVyPUCuNlk5ODJizszN	M{nRdXNCVkeHUh?=
COLO-829	NXexOYVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrDTYFrUUN3ME2wMlI6QDR3IN88US=>	M1zE[nNCVkeHUh?=
MSTO-211H	NUTYSnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jLUGlEPTB;MD6yPVg2PSEQvF2=	NWH4T3NEW0GQR1XS
MDA-MB-361	NWHKbWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\RZndKSzVyPUCuNlk5QTZizszN	MlLmV2FPT0WU
FTC-133	NYXtfGQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjXTWM2OD1yLkOwNlY2KM7:TR?=	Mlz6V2FPT0WU
Mewo	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwM{C0N\|Eh\|ryP	NGmyXYJUSU6JRWK=
HCC70	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXMTWM2OD1yLkOwOlY2KM7:TR?=	NHHsZXBUSU6JRWK=
BB30-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vlbGlEPTB;MD6zNVUzPSEQvF2=	M3j6TnNCVkeHUh?=
LCLC-97TM1	NHru[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjrTWM2OD1yLkOxOVY3KM7:TR?=	Mn70V2FPT0WU
HCC2998	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3UTWM2OD1yLkOxOlUh\|ryP	NIPoUoVUSU6JRWK=
NBsusSR	M3fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH3TWM2OD1yLkOxPFE6KM7:TR?=	M2HPTnNCVkeHUh?=
OVCAR-4	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[yTWM2OD1yLkOyNFIyKM7:TR?=	M3PQ[3NCVkeHUh?=
NCI-H209	M{Pxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETDW4xKSzVyPUCuN\|I{PTNizszN	MnexV2FPT0WU
ChaGo-K-1	NUC0UXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHYeoV6UUN3ME2wMlMzPDh7IN88US=>	Mle0V2FPT0WU
KALS-1	NFrpOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XLeGlEPTB;MD6zNlU6PCEQvF2=	NX\TfVczW0GQR1XS
D-423MG	NILo[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrRTWM2OD1yLkOzNVQzKM7:TR?=	Ml7BV2FPT0WU
Detroit562	NXvKfmluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f0WWlEPTB;MD6zN\|M1OyEQvF2=	NHXLToVUSU6JRWK=
HT-144	NF7WPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV76WnpnUUN3ME2wMlM{QDFizszN	MofUV2FPT0WU
MEG-01	NEDjVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLXd2RDUUN3ME2wMlM1PTh2IN88US=>	MXzTRW5ITVJ?
BV-173	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnC[HpKSzVyPUCuN\|Q2QTZizszN	MX3TRW5ITVJ?
MZ7-mel	MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPaTWM2OD1yLkO0Olc4KM7:TR?=	MYDTRW5ITVJ?
C32	M4LsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHmTYhKSzVyPUCuN\|Q3QDJizszN	NHu0SFlUSU6JRWK=
DU-4475	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUe3fXB3UUN3ME2wMlM1QDd3IN88US=>	NW\EXpczW0GQR1XS
KP-N-YN	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\ZUGlEPTB;MD6zOFg5PyEQvF2=	NF;VZWlUSU6JRWK=
MKN1	NFLaTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmGzTWM2OD1yLkO1NFAzKM7:TR?=	MWfTRW5ITVJ?
8505C	M1rKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwM{WwNFIh\|ryP	MlTwV2FPT0WU
OVCAR-8	NEfRUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL2c4RqUUN3ME2wMlM2PTh2IN88US=>	M3\tUHNCVkeHUh?=
NH-12	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwM{W2PVYh\|ryP	MmDiV2FPT0WU
COR-L88	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjUTWM2OD1yLkO2OFgzKM7:TR?=	M1SzNnNCVkeHUh?=
T-24	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwM{[5PFUh\|ryP	MV\TRW5ITVJ?
MIA-PaCa-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3IPFRrUUN3ME2wMlM4PDl5IN88US=>	M2TPO3NCVkeHUh?=
LS-411N	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX6wTFRSUUN3ME2wMlM4PjB4IN88US=>	NY\rfJpzW0GQR1XS
TK10	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnlSotKSzVyPUCuN\|c6PDhizszN	Mlm3V2FPT0WU
SW1990	M4HGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XWbmlEPTB;MD6zPFM2OyEQvF2=	Mly3V2FPT0WU
GAMG	NXfXXo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m2Z2lEPTB;MD6zPFU3PyEQvF2=	NFrJO\|dUSU6JRWK=
G-361	NVXIZoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPBTWM2OD1yLkO4O\|EzKM7:TR?=	Mlf1V2FPT0WU
Ca-Ski	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwM{i3PVIh\|ryP	MUPTRW5ITVJ?
786-0	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfmTWM2OD1yLkO4PFI{KM7:TR?=	M1TFcXNCVkeHUh?=
MHH-NB-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwM{i5O{DPxE1?	MWfTRW5ITVJ?
OE33	M1nmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUP0eWhCUUN3ME2wMlM6OTF6IN88US=>	MlT5V2FPT0WU
SW954	NGf3NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTMUlFbUUN3ME2wMlQxOTNzIN88US=>	NWrveJVsW0GQR1XS
KYSE-180	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjYdoV7UUN3ME2wMlQxOTVzIN88US=>	NYnNXZNrW0GQR1XS
NCI-H720	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H1NWlEPTB;MD60NFE6OSEQvF2=	NV3WNIkyW0GQR1XS
COR-L23	NWSyXHFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DFNGlEPTB;MD60NFI5PiEQvF2=	Ml\FV2FPT0WU
PFSK-1	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXH4ZndjUUN3ME2wMlQyODl{IN88US=>	MWDTRW5ITVJ?
FADU	NVPI[4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1KyXmlEPTB;MD60NVE4OiEQvF2=	MWrTRW5ITVJ?
GP5d	M1L6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17qXGlEPTB;MD60NVIzPSEQvF2=	M4iwSXNCVkeHUh?=
PC-14	M3TKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj6TWM2OD1yLkSxOlYyKM7:TR?=	NUDUUZJpW0GQR1XS
SJSA-1	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvvcHFKSzVyPUCuOFE4OTRizszN	Mn3nV2FPT0WU
D-336MG	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrtSYNvUUN3ME2wMlQzOTN6IN88US=>	M3zPb3NCVkeHUh?=
LOXIMVI	NY\YPVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwNEK4PFUh\|ryP	MkDhV2FPT0WU
EFO-27	M2rkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwNEOwOFkh\|ryP	NWDsTpRIW0GQR1XS
A2780	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwNEOxOlIh\|ryP	MX;TRW5ITVJ?
CAL-12T	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDTcIpGUUN3ME2wMlQ{Ojh6IN88US=>	NHT1[4RUSU6JRWK=
ES6	NHXIfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvDTWM2OD1yLkS0NVg2KM7:TR?=	MVHTRW5ITVJ?
HCE-T	M370bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwNESxPFch\|ryP	M1\QUHNCVkeHUh?=
SK-MES-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO4XY5IUUN3ME2wMlQ1Ojl\|IN88US=>	NGrz[IRUSU6JRWK=
Daoy	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XpVmlEPTB;MD60OVExOyEQvF2=	MXnTRW5ITVJ?
A2058	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nuWWlEPTB;MD60OVE{PiEQvF2=	NFO0NWJUSU6JRWK=
Hs-578-T	NFjae4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC1TWM2OD1yLkS1Nlc5KM7:TR?=	M2rTenNCVkeHUh?=
TE-11	NX\rPZBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwNEWyPVMh\|ryP	NUTZUpM{W0GQR1XS
GI-ME-N	NYXHW3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPzem0yUUN3ME2wMlQ2PDZizszN	NELvdmdUSU6JRWK=
D-392MG	NH7hTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LF[WlEPTB;MD60OVYyOiEQvF2=	NX;rT4NwW0GQR1XS
MOLT-13	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\0TWM2OD1yLkS2Nlk1KM7:TR?=	MoDYV2FPT0WU
SK-NEP-1	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3r3T2lEPTB;MD60OlQyQSEQvF2=	NYriR4p4W0GQR1XS
KS-1	NHX5VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrmS49GUUN3ME2wMlQ3PjB\|IN88US=>	MY\TRW5ITVJ?
HuP-T4	NITtZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjRT21QUUN3ME2wMlQ3QDZ6IN88US=>	NUfxfJlrW0GQR1XS
NCI-H1563	M135VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNEewN\|Uh\|ryP	MnzTV2FPT0WU
U031	NIXRT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNEiyN\|Qh\|ryP	MnrmV2FPT0WU
HSC-3	M{LDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnBTWM2OD1yLkS4OlI3KM7:TR?=	M4\Hc3NCVkeHUh?=
HT-3	NIG1S\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H5TmlEPTB;MD60PVA{KM7:TR?=	NUHCdpNRW0GQR1XS
HGC-27	M2f2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwNEmxNVUh\|ryP	M4jFcnNCVkeHUh?=
HT-1080	NVXRSpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7HTWM2OD1yLkS5Nlch\|ryP	MlG3V2FPT0WU
RT-112	NIiwSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwNEm5NlEh\|ryP	MXrTRW5ITVJ?
A375	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwNEm5NlIh\|ryP	MWHTRW5ITVJ?
SW626	NGTT[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7DZYpEUUN3ME2wMlUxPjN\|IN88US=>	MYrTRW5ITVJ?
SBC-5	NGjCb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHJTWM2OD1yLkWxN\|Q1KM7:TR?=	NFf4R3RUSU6JRWK=
CAL-51	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\HZ2lEPTB;MD61NVQ{PyEQvF2=	NVXrT2FbW0GQR1XS
RKO	NYDtcolsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rKW2lEPTB;MD61NlAyQSEQvF2=	MlvoV2FPT0WU
HC-1	NWLVd3pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwNUKxNVQh\|ryP	Mo\XV2FPT0WU
CHL-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HBbWlEPTB;MD61NlU2OSEQvF2=	MVzTRW5ITVJ?
SK-N-DZ	M{XrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD4TWM2OD1yLkWzNFc5KM7:TR?=	NG\3[2VUSU6JRWK=
SNU-423	NVS1V455T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGf5VWdKSzVyPUCuOVM1PjZizszN	M2Xhd3NCVkeHUh?=
NB13	NVTLZlRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlqxTWM2OD1yLkWzOlU4KM7:TR?=	MVHTRW5ITVJ?
EW-16	M{HTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwNUO3O\|Qh\|ryP	MYnTRW5ITVJ?
A704	NEHNSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jPZmlEPTB;MD61N\|g5OSEQvF2=	NGHz[oJUSU6JRWK=
Ca9-22	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjMSnpKSzVyPUCuOVQxPzdizszN	Ml3uV2FPT0WU
NCI-H1299	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwNUW1PEDPxE1?	NH[5fnhUSU6JRWK=
LB771-HNC	NXuyOZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWG5R2R5UUN3ME2wMlU2QTN\|IN88US=>	Mn\yV2FPT0WU
EW-11	NF\HSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;HNGlqUUN3ME2wMlU3OzJ4IN88US=>	NWnMdVhCW0GQR1XS
LC-2-ad	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwNU[1NlIh\|ryP	NWfuVIxwW0GQR1XS
KNS-62	NYXBRmQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1THXGlEPTB;MD61OlU2OyEQvF2=	MoTiV2FPT0WU
CAL-62	NEfId2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLrc4xKSzVyPUCuOVcyOjFizszN	MXrTRW5ITVJ?
SF126	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrzTIdKSzVyPUCuOVc1OjFizszN	NIH3NW1USU6JRWK=
OMC-1	NYnzTo9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jQeGlEPTB;MD61O\|Q6PyEQvF2=	MoLMV2FPT0WU
AGS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwNUixOlIh\|ryP	MYTTRW5ITVJ?
EW-22	NEX3ZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwNUizO\|Uh\|ryP	MkO0V2FPT0WU
KP-N-YS	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrWWWVKSzVyPUCuOVg{QDJizszN	MYfTRW5ITVJ?
BFTC-909	NW\QZlFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHS5bGpKSzVyPUCuOVg5OzNizszN	NEfpSVhUSU6JRWK=
PSN1	M3m2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvxWW5GUUN3ME2wMlU6OTF6IN88US=>	MX\TRW5ITVJ?
NB10	M3TER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnSeGpKSzVyPUCuOVkyOjlizszN	Ml7yV2FPT0WU
COLO-800	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\oTWM2OD1yLk[wN\|I5KM7:TR?=	M4jWPXNCVkeHUh?=
647-V	NHG0c3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwNkG3PFch\|ryP	M1TE[3NCVkeHUh?=
VM-CUB-1	M3Tydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nnXGlEPTB;MD62NVg3OSEQvF2=	NGrldJlUSU6JRWK=
OS-RC-2	NIXuTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwNkKwNUDPxE1?	M4r6UXNCVkeHUh?=
IST-SL1	M17s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;LeFNKSzVyPUCuOlI4QDhizszN	NIXaPZNUSU6JRWK=
NCI-H661	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNkO3NVIh\|ryP	NVHDbmF1W0GQR1XS
ETK-1	M3r3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TmWGlEPTB;MD62N\|czOSEQvF2=	MkTqV2FPT0WU
SW1710	NYDUfodNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTqTWM2OD1yLk[0NFI{KM7:TR?=	NV\TcZRKW0GQR1XS
GCT	NYLLWW92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[wfXFjUUN3ME2wMlY1QTN3IN88US=>	NIjHV21USU6JRWK=
SKG-IIIa	NFHBRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C4S2lEPTB;MD62OVA{PiEQvF2=	NWnJXW1FW0GQR1XS
LU-134-A	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fld2lEPTB;MD62OVY2KM7:TR?=	MlrXV2FPT0WU
Becker	M{HNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjYNnpKSzVyPUCuOlU5ODVizszN	NHHsVXdUSU6JRWK=
PANC-08-13	NWjRT3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwNk[wOlgh\|ryP	MXHTRW5ITVJ?
SW620	NHnwPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrhb3RGUUN3ME2wMlY3OjJ\|IN88US=>	M{f1W3NCVkeHUh?=
AsPC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHmVHNpUUN3ME2wMlY3OzZzIN88US=>	NIjYW5VUSU6JRWK=
LXF-289	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwNke2NlUh\|ryP	MX7TRW5ITVJ?
RERF-LC-MS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7MTWM2OD1yLk[3OlcyKM7:TR?=	Mm\MV2FPT0WU
NCI-H1355	NUfQeWRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO4[VhKSzVyPUCuOlc5PTJizszN	M4TOUXNCVkeHUh?=
23132-87	M3vS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzUd5NKSzVyPUCuOlg{ODZizszN	Mki0V2FPT0WU
BHY	MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP6WmpKSzVyPUCuOlg5ODRizszN	M4eyNnNCVkeHUh?=
C2BBe1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[xTWM2OD1yLk[4PVI5KM7:TR?=	NHL4WoVUSU6JRWK=
A172	M{TuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi3TWM2OD1yLk[5NlE4KM7:TR?=	NHrlVY9USU6JRWK=
NCI-H727	NIPjeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoW2TWM2OD1yLk[5PFEzKM7:TR?=	NVXTcJFiW0GQR1XS
NB69	M{nFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjVZohKSzVyPUCuO\|A2PDlizszN	M4nqdnNCVkeHUh?=
HCC1937	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi4T\|NKSzVyPUCuO\|A3OzFizszN	NEXITnJUSU6JRWK=
HuCCT1	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HpWWlEPTB;MD63NFc3PSEQvF2=	M1n5[3NCVkeHUh?=
HH	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XtNmlEPTB;MD63NFc5OSEQvF2=	MWjTRW5ITVJ?
MN-60	NH7sfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDNVZp6UUN3ME2wMlczOTJ2IN88US=>	MUTTRW5ITVJ?
CFPAC-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\h[2lEPTB;MD63NlI2PyEQvF2=	MoHJV2FPT0WU
HOP-62	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;EbVBXUUN3ME2wMlczPjJizszN	MkLWV2FPT0WU
EW-3	NYDCVoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LtPWlEPTB;MD63N\|U2OiEQvF2=	Mmn0V2FPT0WU
SW1417	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYmyXWdiUUN3ME2wMlc{PTl\|IN88US=>	NV7mcXdyW0GQR1XS
NCI-H1155	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwN{O4OlQh\|ryP	Ml;mV2FPT0WU
CAL-54	NYHrcYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzPPItKSzVyPUCuO\|QxOyEQvF2=	MkLrV2FPT0WU
Saos-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPubVZoUUN3ME2wMlc1PTh2IN88US=>	NXjjUo9DW0GQR1XS
NCI-H446	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PCO2lEPTB;MD63OFgxPiEQvF2=	M3;mdHNCVkeHUh?=
LS-513	NITMPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrQbWtKSzVyPUCuO\|Q6ODhizszN	MWfTRW5ITVJ?
PA-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjMTWM2OD1yLke0PVY5KM7:TR?=	NVjFSFNWW0GQR1XS
HCC38	NXLrc3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwN{S5PFQh\|ryP	MWTTRW5ITVJ?
DMS-273	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwN{W0OVYh\|ryP	M1fOSnNCVkeHUh?=
U-266	NF;4VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzKTWM2OD1yLke2NlYzKM7:TR?=	MnfzV2FPT0WU
HL-60	NYLRbGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwN{ezOVUh\|ryP	MXrTRW5ITVJ?
UACC-62	M3Oxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwN{e1OVMh\|ryP	MVLTRW5ITVJ?
DoTc2-4510	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvjTWM2OD1yLke4NlEyKM7:TR?=	NIHQOnBUSU6JRWK=
SW982	NVrvfZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwN{i0N\|Ih\|ryP	NEPodnJUSU6JRWK=
8305C	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O1NGlEPTB;MD63PFk{QSEQvF2=	NH7DSGpUSU6JRWK=
SW48	NGHJVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHrVnBCUUN3ME2wMlc6OjRizszN	MYXTRW5ITVJ?
NB5	NGHQPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{ewRWlEPTB;MD63PVY2OSEQvF2=	MWPTRW5ITVJ?
J82	NUHMVlliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHPTWM2OD1yLkiwOFg4KM7:TR?=	NFvKOodUSU6JRWK=
HDLM-2	MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln5TWM2OD1yLkixN\|Q6KM7:TR?=	NV3tPGU{W0GQR1XS
HEC-1	M4jRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofUTWM2OD1yLkixN\|cyKM7:TR?=	NHPK[WNUSU6JRWK=
AU565	NWPVRZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\EZoM6UUN3ME2wMlgzPDRizszN	MnvpV2FPT0WU
KYSE-520	M2jtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYW5d5RlUUN3ME2wMlgzPjN4IN88US=>	NICzPZJUSU6JRWK=
HTC-C3	NHGweYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrMTWM2OD1yLkizOFc1KM7:TR?=	M1q4OnNCVkeHUh?=
AN3-CA	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwOEO3NVEh\|ryP	M1r2NHNCVkeHUh?=
KG-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jieGlEPTB;MD64OFQ5PCEQvF2=	M2nidHNCVkeHUh?=
NCI-N87	NEjpZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwOES1OVYh\|ryP	NEKxVnZUSU6JRWK=
HN	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzEOHNKSzVyPUCuPFQ2QTFizszN	MX\TRW5ITVJ?
SiHa	M1LNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX5Z5RNUUN3ME2wMlg2QDh{IN88US=>	M3O5V3NCVkeHUh?=
C-33-A	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zFUmlEPTB;MD64OlE5PSEQvF2=	MlmyV2FPT0WU
A673	NH7O[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEG0N3BKSzVyPUCuPFY2OzZizszN	MWjTRW5ITVJ?
HSC-2	NGjzTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfJTWM2OD1yLki3N\|M1KM7:TR?=	MXfTRW5ITVJ?
LN-405	NHvITmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK4dm5pUUN3ME2wMlg4PzNzIN88US=>	M4DkO3NCVkeHUh?=
HOS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvBTlVKSzVyPUCuPFc6QTVizszN	NWfONoNwW0GQR1XS
SF268	NETCe\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvkfWttUUN3ME2wMlg5ODl5IN88US=>	NW\vfVc4W0GQR1XS
DJM-1	M2PRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfwdJNUUUN3ME2wMlg5PjB{IN88US=>	MonvV2FPT0WU
HT-29	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH25SmRKSzVyPUCuPFk1OTdizszN	NV3B[HU5W0GQR1XS
NCI-H292	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzoV2hnUUN3ME2wMlg6Pzd5IN88US=>	MofYV2FPT0WU
UM-UC-3	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTjTWM2OD1yLkmwN\|E3KM7:TR?=	Mk[5V2FPT0WU
VMRC-RCZ	NWTBWVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L2[mlEPTB;MD65NFU4QCEQvF2=	NVOxT3VEW0GQR1XS
D-263MG	NYraNFBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzMbY1WUUN3ME2wMlkxQTR\|IN88US=>	NFzPR5NUSU6JRWK=
TE-10	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknVTWM2OD1yLkmwPVg1KM7:TR?=	NGL2ZZhUSU6JRWK=
SW1088	NGT0eFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwOUG1OVIh\|ryP	MnnJV2FPT0WU
NCI-H1048	M3G2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwOUG4OVIh\|ryP	MUDTRW5ITVJ?
A431	NVm2c3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwOUK0OVIh\|ryP	NX\ie2VrW0GQR1XS
SW1783	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH64W2ZKSzVyPUCuPVMzPTFizszN	MnXlV2FPT0WU
NCI-H2452	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nrV2lEPTB;MD65N\|U2PyEQvF2=	M3ewUnNCVkeHUh?=
OAW-42	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4KwU2lEPTB;MD65N\|Y3PSEQvF2=	MXfTRW5ITVJ?
HuO-3N1	NXvCRoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfJbmR7UUN3ME2wMlk1ODl{IN88US=>	MnfpV2FPT0WU
K5	NIjafVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwOUSxNlch\|ryP	NUXORmJ5W0GQR1XS
SW1573	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPUfm1KSzVyPUCuPVQzOjdizszN	M3TRSXNCVkeHUh?=
NCI-H1792	M3robGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\RZmlEPTB;MD65OFI{PyEQvF2=	NHnJeGFUSU6JRWK=
HCC1187	M{DBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fafWlEPTB;MD65Olc1QSEQvF2=	NFuzUoVUSU6JRWK=
HCE-4	NFXsdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXlTWM2OD1yLkm2PVYh\|ryP	NH\4NJNUSU6JRWK=
HPAF-II	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\LUIpGUUN3ME2wMlk4ODJ6IN88US=>	MoWyV2FPT0WU
MEL-HO	M{TnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XHXWlEPTB;MD65O\|k1PSEQvF2=	NFHBc5RUSU6JRWK=
LCLC-103H	M3HFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwOUiwNlch\|ryP	MlnGV2FPT0WU
CAL-33	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTTW2dKSzVyPUCuPVg{PzhizszN	NWrmPI9YW0GQR1XS
NB6	NFXuZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwOUi0OlIh\|ryP	NWrj[md2W0GQR1XS
BFTC-905	NWrxUlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPRTWM2OD1yLkm4OFc{KM7:TR?=	NFq2VmZUSU6JRWK=
NMC-G1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\R[4xjUUN3ME2wMlk5PTl{IN88US=>	NVm3eJNTW0GQR1XS
RCM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDIZ5h[UUN3ME2wMlk6OjV6IN88US=>	MkK5V2FPT0WU
COLO-320-HSR	NGfzSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDFTWM2OD1zLkCwOFEzKM7:TR?=	NXnaUmlNW0GQR1XS
NCI-H2030	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jDOGlEPTB;MT6wNVgyOyEQvF2=	NW\iSJp2W0GQR1XS
SCC-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\ZTmlEPTB;MT6wNVg2QSEQvF2=	MUPTRW5ITVJ?
KYSE-410	NGLvUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3mWGRpUUN3ME2xMlA{PTJizszN	MUDTRW5ITVJ?
NCI-H1650	NGTtbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfMTWM2OD1zLkCzPVcyKM7:TR?=	MW\TRW5ITVJ?
S-117	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:5TXNKSzVyPUGuNFQh\|ryP	NETqOpZUSU6JRWK=
GAK	NH3wWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnaTmhKSzVyPUGuNFUxPzVizszN	NFXZfolUSU6JRWK=
KYSE-450	NYfLOHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXnSlNKSzVyPUGuNFU{OzZizszN	MmW0V2FPT0WU
M059J	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrnOWx5UUN3ME2xMlA3QDJ6IN88US=>	NWXvdpBXW0GQR1XS
LAN-6	NW\nVIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\MdIhKSzVyPUGuNFc4PzNizszN	Mn71V2FPT0WU
NCI-H1651	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwMEmzOVIh\|ryP	M{DPcHNCVkeHUh?=
KMOE-2	M4DFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFwMUC5O\|Mh\|ryP	Mn3oV2FPT0WU
SN12C	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTtRlRyUUN3ME2xMlEyPzh3IN88US=>	MkK3V2FPT0WU
SW900	NUjLN\|VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zlVWlEPTB;MT6xNlI2OSEQvF2=	NY\6U41UW0GQR1XS
TE-8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi3RodKSzVyPUGuNVIzQTFizszN	NIS0OnlUSU6JRWK=
HO-1-N-1	M3zmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTFwMUSzOVMh\|ryP	NFPRPFlUSU6JRWK=
BHT-101	M1SzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrtTWM2OD1zLkG0O\|E1KM7:TR?=	NH\HN45USU6JRWK=
639-V	M{C5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{frNmlEPTB;MT6xOlY4KM7:TR?=	M1LZXHNCVkeHUh?=
RVH-421	NFz4e\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFwMUmzOFch\|ryP	MUfTRW5ITVJ?
SW780	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPsU4FqUUN3ME2xMlE6PTF3IN88US=>	NIXXVGVUSU6JRWK=
SNB75	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jJ[WlEPTB;MT6xPVgyQSEQvF2=	NIL0TWVUSU6JRWK=
U-87-MG	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\FWY9KSzVyPUGuNlE{OzRizszN	MUHTRW5ITVJ?
TE-1	NV;3TW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\5bIZWUUN3ME2xMlIyOzZ5IN88US=>	NFq5cFRUSU6JRWK=
CAS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDlVFVKSzVyPUGuNlE1OThizszN	MoPQV2FPT0WU
MKN7	M2Pi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P5W2lEPTB;MT6yNVQ4QCEQvF2=	NUfzOYRbW0GQR1XS
KM-H2	NXy4Rm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrHTWM2OD1zLkKxO\|c{KM7:TR?=	M1zTV3NCVkeHUh?=
NCI-H1693	NWrYfGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWKzbWJ7UUN3ME2xMlIzPzV6IN88US=>	MkH1V2FPT0WU
KGN	NXHBc4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFwMkOzOVkh\|ryP	MkPBV2FPT0WU
NCI-H2347	M3LjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPHW\|VKSzVyPUGuNlM2OjVizszN	Ml2xV2FPT0WU
MFM-223	NIfZT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEKzR49KSzVyPUGuNlQ{PDNizszN	NEjme2tUSU6JRWK=
OCI-AML2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPrcWdMUUN3ME2xMlI3PjZ4IN88US=>	MnO2V2FPT0WU
SAS	NYj2doJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CyNGlEPTB;MT6yOlY4OiEQvF2=	MlLVV2FPT0WU
BT-549	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fJNWlEPTB;MT6yOlc5OiEQvF2=	MoPyV2FPT0WU
NCI-H2228	NWfDZXFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTNTWM2OD1zLkK4OlQh\|ryP	MlfyV2FPT0WU
BxPC-3	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXwTWM2OD1zLkOwOlczKM7:TR?=	MYDTRW5ITVJ?
SCH	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjQZWM{UUN3ME2xMlMzPTB\|IN88US=>	NVvvVlNIW0GQR1XS
GMS-10	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\EUndKSzVyPUGuN\|Q2PTFizszN	M2nKWXNCVkeHUh?=
GB-1	M4HzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF72NXpKSzVyPUGuN\|c2PjRizszN	M3r5VHNCVkeHUh?=
NCI-H520	M1nOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknGTWM2OD1zLkO4NVY5KM7:TR?=	NX\k[2VyW0GQR1XS
GCIY	NFSyU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnqyTWM2OD1zLkO5NFUyKM7:TR?=	MUDTRW5ITVJ?
HuH-7	NHPTfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTFwM{m1NFEh\|ryP	NU\VR5hUW0GQR1XS
IA-LM	NUTJW4hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmf6TWM2OD1zLkO5PVg3KM7:TR?=	M4rNZnNCVkeHUh?=
BB49-HNC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFwNECyN\|Eh\|ryP	NF\POmNUSU6JRWK=
Calu-6	NVnw[29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPaXJJKSzVyPUGuOFEyQDdizszN	M1jYenNCVkeHUh?=
NCI-H650	M1XMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS5TWM2OD1zLkSxO\|k2KM7:TR?=	M17pN3NCVkeHUh?=
TE-5	NITaO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTFwNEG5OVQh\|ryP	NHjjWGVUSU6JRWK=
KINGS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwNEKwNVgh\|ryP	NWXNNJpDW0GQR1XS
HCT-116	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\SeWhKSzVyPUGuOFIyPzZizszN	M2jQR3NCVkeHUh?=
NCI-H1573	NUDMcYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjHSnZKSzVyPUGuOFIzPTdizszN	M1ztXnNCVkeHUh?=
NCI-H358	NIm0N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFwNEOxNlgh\|ryP	NVu5U5NoW0GQR1XS
LNCaP-Clone-FGC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrLS3VKSzVyPUGuOFQ{OTlizszN	NGHaZ21USU6JRWK=
KP-4	NGrHUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvmcFNIUUN3ME2xMlQ3OTVzIN88US=>	MnHrV2FPT0WU
LK-2	NFPie2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjqNWJKSzVyPUGuOFY{QDJizszN	MmHVV2FPT0WU
EFM-19	NXrkepFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXwNYhKSzVyPUGuOFgyODRizszN	M4L0cXNCVkeHUh?=
GT3TKB	M3zOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7NboFKSzVyPUGuOFg3OTNizszN	NI\2[lVUSU6JRWK=
A549	NIDsb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfFV4JKSzVyPUGuOFg5OzNizszN	NXfPWHdxW0GQR1XS
no-11	NFPGUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTFwNEmwNlYh\|ryP	NH;yW\|JUSU6JRWK=
SK-N-FI	NYjwSnY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH6[HhGUUN3ME2xMlQ6OzhizszN	MnfGV2FPT0WU
NCI-H2170	NITt[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G1OmlEPTB;MT61NlMyOyEQvF2=	MXnTRW5ITVJ?
NCI-H460	NUPUUnZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFwNUK5OlEh\|ryP	M1HqenNCVkeHUh?=
NCI-H526	NHjDfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TpPWlEPTB;MT61N\|cxPiEQvF2=	NH\MNGxUSU6JRWK=
KYSE-510	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojKTWM2OD1zLkW4NlUh\|ryP	NEDtdlFUSU6JRWK=
YKG-1	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P6PWlEPTB;MT61PFMzQCEQvF2=	M{O2d3NCVkeHUh?=
EW-18	NHfxe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LXbWlEPTB;MT62NFIzPyEQvF2=	NHzPe2JUSU6JRWK=
MDA-MB-231	NXL1TG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz6TWM2OD1zLk[wN\|gh\|ryP	NHjaOGpUSU6JRWK=
HT55	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXiTWM2OD1zLk[wOVkyKM7:TR?=	M1HTUHNCVkeHUh?=
NCI-H1793	M4CwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M362dmlEPTB;MT62NVM1PSEQvF2=	M3TjOnNCVkeHUh?=
TE-9	NXTH[FNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDrZpBKSzVyPUGuOlM1PTZizszN	MWnTRW5ITVJ?
DSH1	NHzoOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq1bIxKSzVyPUGuOlkzPTZizszN	MmfJV2FPT0WU
A101D	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXaTWM2OD1zLk[5PVg{KM7:TR?=	NFjkUFNUSU6JRWK=
DB	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDQXJFKSzVyPUGuO\|AxPjdizszN	NXnFRXpJW0GQR1XS
ME-180	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DPZmlEPTB;MT63NVc5PSEQvF2=	M3X3W3NCVkeHUh?=
BT-20	NIjmW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjtdWlEUUN3ME2xMlczPDB5IN88US=>	NFX1VnBUSU6JRWK=
A498	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrXOmtXUUN3ME2xMlczQTZ\|IN88US=>	NHrhRZJUSU6JRWK=
UMC-11	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwN{[3OFkh\|ryP	MlrwV2FPT0WU
EC-GI-10	NEjPdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX70fo4xUUN3ME2xMlc4PTV4IN88US=>	MYTTRW5ITVJ?
NCI-H630	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjJ[3l6UUN3ME2xMlc5PjR{IN88US=>	NIDvW5pUSU6JRWK=
EGI-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXnWZJKSzVyPUGuPFAzPjdizszN	NHPWVpFUSU6JRWK=
22RV1	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnZTWM2OD1zLkiwPFU{KM7:TR?=	M3j3dXNCVkeHUh?=
LS-123	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIP0WHJKSzVyPUGuPFEzOTRizszN	M1HJOHNCVkeHUh?=
OAW-28	M1\BZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Hye2lEPTB;MT64OFc1PiEQvF2=	Mlv1V2FPT0WU
CaR-1	NHLafHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFwOEewO{DPxE1?	NFzXcXNUSU6JRWK=
HT	NIfWUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInBPWFKSzVyPUGuPFc{PDJizszN	NIW1XmJUSU6JRWK=
BCPAP	NXH4b5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoToTWM2OD1zLki4Olc3KM7:TR?=	NIDMTFFUSU6JRWK=
RMG-I	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH6[nJKSzVyPUGuPVA4QDdizszN	NULleI0xW0GQR1XS
C8166	NE\2PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jqNGlEPTB;MT65NFk{OiEQvF2=	MlrhV2FPT0WU
TGBC1TKB	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TzUGlEPTB;MT65NlA{PSEQvF2=	NGmwXFBUSU6JRWK=
SCC-9	NYXJ[3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFwOUmxNFUh\|ryP	NVGzO2VVW0GQR1XS
EKVX	NVuwcWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXnblVKSzVyPUKuNFAyPTRizszN	NFnFRoRUSU6JRWK=
KU-19-19	NGfrWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTQR4w2UUN3ME2yMlAxOzd{IN88US=>	MkPWV2FPT0WU
K-562	M3HCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfkfJVKSzVyPUKuNFA5QThizszN	MUnTRW5ITVJ?
SW962	NIHVeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHmfohKSzVyPUKuNFQxPTlizszN	NFW2doFUSU6JRWK=
MDA-MB-453	M2L6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\1dI9CUUN3ME2yMlA2PDR{IN88US=>	M2CxdHNCVkeHUh?=
BPH-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvvTWM2OD1{LkC3NFk5KM7:TR?=	M{XLN3NCVkeHUh?=
DK-MG	M{\zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf0VIxKSzVyPUKuNFg3ODNizszN	MXPTRW5ITVJ?
Capan-2	NWHGZYpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO3TWM2OD1{LkGwNFQyKM7:TR?=	NWn1bJU2W0GQR1XS
SCC-15	M1H4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjmV4dqUUN3ME2yMlEzPTRzIN88US=>	NV75SIJoW0GQR1XS
DOK	NV\WSIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjqZ3JKSzVyPUKuNVMyPDdizszN	MUTTRW5ITVJ?
YAPC	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\JS2FZUUN3ME2yMlE2OzB5IN88US=>	MUnTRW5ITVJ?
AM-38	M2n3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTJwMUewNVUh\|ryP	NYnGUFVqW0GQR1XS
EFO-21	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnIWWhKSzVyPUKuNVc4QDhizszN	M37wc3NCVkeHUh?=
A388	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEX1TpVKSzVyPUKuNVkzPzFizszN	MnfsV2FPT0WU
RH-18	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPaTWM2OD1{LkG5N\|Y6KM7:TR?=	MoHyV2FPT0WU
NCI-H1581	M4f1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[4TWM2OD1{LkG5OVk3KM7:TR?=	NVX3OYFIW0GQR1XS
COLO-668	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXnfFJKSzVyPUKuNlk6PzNizszN	NVvCfFlpW0GQR1XS
RPMI-2650	NH\3dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvhe3BKSzVyPUKuN\|I3PTlizszN	MXjTRW5ITVJ?
HMV-II	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnDSGxKSzVyPUKuN\|M5PjhizszN	MUnTRW5ITVJ?
NCI-H2342	M3H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4f2dWlEPTB;Mj6zOFYxOyEQvF2=	MXHTRW5ITVJ?
SH-4	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnTTWM2OD1{LkO4NlA1KM7:TR?=	M3XN[XNCVkeHUh?=
L-428	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr3WpdKSzVyPUKuN\|g4QTRizszN	MVXTRW5ITVJ?
U-118-MG	NX65cYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OwNGlEPTB;Mj6zPVgxPSEQvF2=	MkCyV2FPT0WU
RO82-W-1	NYnTNlJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HpNmlEPTB;Mj60N\|czPyEQvF2=	MVXTRW5ITVJ?
NCI-H2291	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTJwNE[5PVQh\|ryP	M2XzenNCVkeHUh?=
SK-OV-3	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zjUGlEPTB;Mj61NFI1QSEQvF2=	MWDTRW5ITVJ?
NCI-H441	M4\3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mly5TWM2OD1{LkWwN\|A2KM7:TR?=	NVnWNHlpW0GQR1XS
NCI-H2009	NYrHO2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPkS\|l5UUN3ME2yMlUzQTN2IN88US=>	MYnTRW5ITVJ?
LB2518-MEL	NGjrN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTJwNUO3OFch\|ryP	MYnTRW5ITVJ?
PANC-10-05	NYjwUpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPlTnpSUUN3ME2yMlYyOTF4IN88US=>	M2fTXXNCVkeHUh?=
CAL-85-1	NFj5[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETyU2FKSzVyPUKuOlYyPjFizszN	NEfwVYJUSU6JRWK=
PC-3	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;Zc\|lKSzVyPUKuOlY3OTFizszN	NF;QfHhUSU6JRWK=
COLO-824	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;LTWM2OD1{Lk[3N\|c1KM7:TR?=	M3ToWnNCVkeHUh?=
D-502MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTJwN{C0NFYh\|ryP	MkW1V2FPT0WU
SBC-1	NYDKTVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz1TWM2OD1{LkexOlI4KM7:TR?=	NEW5PGNUSU6JRWK=
CAPAN-1	M2rBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3JTWM2OD1{LkexPVQ6KM7:TR?=	MmLoV2FPT0WU
D-247MG	NVLtb\|JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTJwN{O3OVYh\|ryP	NF\5U3VUSU6JRWK=
CAL-39	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f1emlEPTB;Mj64OlM5QSEQvF2=	Ml\kV2FPT0WU
NCI-H2087	NWHLWm1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHUZVNKUUN3ME2yMlg5PDNzIN88US=>	MnvPV2FPT0WU
NB7	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\sOVZKSzVyPUKuPVIyOzlizszN	MVrTRW5ITVJ?
NCI-H1437	M1\sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfBc4xQUUN3ME2yMlkzOjV5IN88US=>	Mo\WV2FPT0WU
RD	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTJwOUm5N\|kh\|ryP	NFXjUJNUSU6JRWK=
TCCSUP	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\Ld\|BiUUN3ME2zMlAzPjN4IN88US=>	Mln1V2FPT0WU
MKN28	M3PkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPHdXI3UUN3ME2zMlA{PDZ\|IN88US=>	MULTRW5ITVJ?
NCI-H596	M3LSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXoTWM2OD1\|LkC2O\|Eh\|ryP	MVLTRW5ITVJ?
SW948	NGXpOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPtfo9KSzVyPUOuNFk3QTNizszN	NGqySYZUSU6JRWK=
WM-115	M{LLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1m4cmlEPTB;Mz6xNVgzPyEQvF2=	NXTVWlVmW0GQR1XS
HCC1954	NEPsfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTNwMUKxOFEh\|ryP	MWjTRW5ITVJ?
MS-1	NU\aUlZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjBV3ZFUUN3ME2zMlE5PDd2IN88US=>	MYDTRW5ITVJ?
SW13	M1;OWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHHPZBKSzVyPUOuNlMzPiEQvF2=	M4SzNnNCVkeHUh?=
OE19	M2\IPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTNwMki0PFkh\|ryP	MV\TRW5ITVJ?
HT-1197	NGjOSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[zTWM2OD1\|LkK5NVc6KM7:TR?=	M2\xNXNCVkeHUh?=
HLE	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvsNotKSzVyPUOuN\|I5OSEQvF2=	NWLTV\|BDW0GQR1XS
NUGC-3	NGnncJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PjcmlEPTB;Mz60OFc3OSEQvF2=	Mm\HV2FPT0WU
UACC-257	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[yfFBKSzVyPUOuOVI1OTdizszN	M2rFcXNCVkeHUh?=
SK-MEL-3	NFn4cJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;vTWM2OD1\|LkWzNlE1KM7:TR?=	NFXwcGhUSU6JRWK=
KNS-81-FD	M{LBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rXZmlEPTB;Mz61OlIh\|ryP	M{jSNXNCVkeHUh?=
MZ1-PC	M3zEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\nTWM2OD1\|LkW3PVg3KM7:TR?=	M{X6NnNCVkeHUh?=
KLE	NELUbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljnTWM2OD1\|LkW5PFY4KM7:TR?=	NYjNSWNJW0GQR1XS
NCI-H2052	NXyzb\|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHZZWdIUUN3ME2zMlYxODB7IN88US=>	NVvVSopsW0GQR1XS
NCI-H1838	NH;uZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLYTWM2OD1\|LkixNVE6KM7:TR?=	NX\h[5h4W0GQR1XS
NCI-H1623	M133Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjDTWM2OD12LkCxN\|k3KM7:TR?=	NH;L[JlUSU6JRWK=
SCC-25	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\qcWlKSzVyPUSuNlM2QTdizszN	M4LtVnNCVkeHUh?=
CP66-MEL	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfMb5dKSzVyPUSuNlUyQTFizszN	NVnIVpByW0GQR1XS
TE-12	NGTzVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkSxTWM2OD12LkK5NlcyKM7:TR?=	MlLZV2FPT0WU
LU-99A	NVj4fGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfPTWM2OD12LkOxN\|Q2KM7:TR?=	NU\G[JB1W0GQR1XS
CAMA-1	M4T6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nw[mlEPTB;ND6zOVIh\|ryP	M1viWnNCVkeHUh?=
SK-MEL-30	M{j4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnDO2tKSzVyPUSuOFE6OTNizszN	NFrTfI9USU6JRWK=
KURAMOCHI	M1LScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[3Z\|lKSzVyPUSuOFU2OjhizszN	M1LjPHNCVkeHUh?=
BEN	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTDV3dtUUN3ME20MlUzOzZ{IN88US=>	NVS3UnBwW0GQR1XS
NCI-H226	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjONIxKSzVyPUSuOVQ5PzFizszN	MX7TRW5ITVJ?
CAL-27	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHj3OoxKSzVyPUSuO\|E3QTRizszN	MXjTRW5ITVJ?
G-401	NVzkS2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SxS2lEPTB;ND64N\|g1OSEQvF2=	NGPpZXZUSU6JRWK=
CAL-120	NEH6VI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nyeWlEPTB;ND64OFk6OSEQvF2=	NWHJNYR5W0GQR1XS
DMS-114	NWTycppbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TaUmlEPTB;NT6xOFUxPiEQvF2=	M{jWeHNCVkeHUh?=
KYSE-70	M4POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfZTWM2OD13LkG0PFU6KM7:TR?=	M2TkR3NCVkeHUh?=
NCI-H1648	M1XTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7jTIE2UUN3ME21MlI6Pzh{IN88US=>	NXLybYw4W0GQR1XS
MDA-MB-175-VII	NVS4OIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\De3JZUUN3ME21MlQ1ODF2IN88US=>	Mmf3V2FPT0WU
NCI-H2029	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILOVIJKSzVyPUWuOFgxOjJizszN	NHXUc2FUSU6JRWK=
LS-1034	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\udndlUUN3ME21MlY3QDh7IN88US=>	NUPNXG85W0GQR1XS
LB831-BLC	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTVwN{CzOFUh\|ryP	NX\rXpNIW0GQR1XS
MDA-MB-415	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj2TWM2OD13LkewPFEh\|ryP	MkHXV2FPT0WU
TE-6	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\XTWM2OD13Lke0NVgzKM7:TR?=	NYPoNYdrW0GQR1XS
SK-MEL-24	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTVwN{S1OlQh\|ryP	NInzeolUSU6JRWK=
HUTU-80	NVK1[mxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH34WpBKSzVyPUWuO\|U{OzNizszN	MV\TRW5ITVJ?
OCUB-M	M2jmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTVwN{e1OlMh\|ryP	MlfYV2FPT0WU
IGR-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjJTWM2OD13Lki2PFk1KM7:TR?=	NVq1S416W0GQR1XS
NCI-H747	NWHGWXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4OxNmlEPTB;Nj6yOFU5PSEQvF2=	Mk\YV2FPT0WU
COLO-680N	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K1S2lEPTB;Nj6zPVQxOyEQvF2=	NXPzVHd3W0GQR1XS
NB12	M3PzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVThS3N4UUN3ME22Mlc6PzJ{IN88US=>	MmC2V2FPT0WU
SNU-449	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTZwOUm1PVEh\|ryP	Mmm1V2FPT0WU
D-542MG	NYLPVlRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j4OmlEPTB;Nz6xNlI6QSEQvF2=	MXfTRW5ITVJ?
COLO-792	NIHacJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LRNGlEPTB;Nz64O\|EzPyEQvF2=	MYrTRW5ITVJ?
NCI-H810	M1vvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;BTWM2OD16LkCyPVg1KM7:TR?=	NI\EcIpUSU6JRWK=
T47D	NUfoenFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRThwMU[wNlQh\|ryP	NXTtUZpSW0GQR1XS
Calu-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjufIhlUUN3ME24MlI5QDh4IN88US=>	Mn:zV2FPT0WU
COLO-741	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRThwOUOwPVMh\|ryP	NYLO[GU4W0GQR1XS
LU-135	NEXZT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvafnVKSzVyPUmuNFM1PTJizszN	NXXQ[5V2W0GQR1XS
COLO-678	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2r3bGlEPTB;OT6yPFg1PCEQvF2=	Mm\VV2FPT0WU
NCI-H2126	MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnlbItKSzVyPUmuN\|M6OTlizszN	MX;TRW5ITVJ?
SK-MEL-28	NIjqWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH3bZlWUUN3ME25MlU{PTl4IN88US=>	NEDUT4JUSU6JRWK=
MFE-280	M{LKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XGeWlEPTB;MUCuNFIzQSEQvF2=	NYr5Npd4W0GQR1XS
DBTRG-05MG	NEnjdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\YTWM2OD1zMD60N\|Y6KM7:TR?=	NUXNU5ZRW0GQR1XS
RCC10RGB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnJTWM2OD1zMD61NlU2KM7:TR?=	MkPnV2FPT0WU
NTERA-S-cl-D1	NG\oT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTFyLk[4OVIh\|ryP	MWXTRW5ITVJ?
C3A	NIj3[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjHSo9JUUN3ME2xNk4{OTd{IN88US=>	MVLTRW5ITVJ?
MHH-ES-1	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3jWYFKSzVyPUGyMlUzQDRizszN	NXf0TYNjW0GQR1XS
LU-139	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF{Lk[zN\|Mh\|ryP	NYXGT3hRW0GQR1XS
KNS-42	M1vSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LZWmlEPTB;MUKuPFc4OSEQvF2=	NEjYUplUSU6JRWK=
MCF7	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljJTWM2OD1zMz6yN\|Y2KM7:TR?=	NUXzdHNUW0GQR1XS
SW872	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL2UWVKSzVyPUG0MlU1PjFizszN	NHvoOJNUSU6JRWK=
HT-1376	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnxdlFKSzVyPUG0Mlg2QDJizszN	MVPTRW5ITVJ?
NCI-SNU-5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qzNGlEPTB;MUWuNVc1OSEQvF2=	M3y2NXNCVkeHUh?=
NCI-H2405	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjEWnRiUUN3ME2xOU41PDd2IN88US=>	M1nTT3NCVkeHUh?=
KYSE-150	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnNTWM2OD1zNT63OlEyKM7:TR?=	NVH2UXpWW0GQR1XS
SW837	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PhbGlEPTB;MU[uNFEzPCEQvF2=	M4nqWXNCVkeHUh?=
LU-65	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;ETmlEPTB;MUmuO\|I3KM7:TR?=	M4LMcHNCVkeHUh?=
JEG-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYqzfodmUUN3ME2yNE4{PTd5IN88US=>	NGGxNWRUSU6JRWK=
SK-MEL-1	NHfrV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\tTWM2OD1{MD63PFM3KM7:TR?=	M2jjRXNCVkeHUh?=
SK-HEP-1	M1T4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojpTWM2OD1{MT61OVQyKM7:TR?=	M1LF[XNCVkeHUh?=
NCI-H1770	M{j0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG5XVRPUUN3ME2yN{41ODh4IN88US=>	M33pXXNCVkeHUh?=
MG-63	M3fIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJ\|Lke2O\|Mh\|ryP	M13JbnNCVkeHUh?=
ECC10	NH3RRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHyTWM2OD1{NT61O\|Eh\|ryP	MYnTRW5ITVJ?
SW1463	NGjIWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7BWmZMUUN3ME2yO{45OzF4IN88US=>	M3LEZnNCVkeHUh?=
JVM-2	NHrRbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXmyXpY2UUN3ME2yPE4{OjR6IN88US=>	NEn6dpRUSU6JRWK=
HCT-15	NFi4W3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M373TGlEPTB;MkiuOFE6OiEQvF2=	Mn\iV2FPT0WU
CAL-72	M1yy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTNzLkS5NVIh\|ryP	NWnvPJZOW0GQR1XS
HCC2218	NF\mVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvRPFBKSzVyPUOyMlg5PThizszN	NXH2SIE6W0GQR1XS
BT-474	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fE[mlEPTB;M{OuNFg1OyEQvF2=	Ml3xV2FPT0WU
NCI-H1092	M2n5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHFe2ZpUUN3ME2zN{42OTR3IN88US=>	M3\EbXNCVkeHUh?=
Mo-T	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfRRlRKSzVyPUO3MlM2QDVizszN	Ml\oV2FPT0WU
DU-145	NXqwU5NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm4TWM2OD12MD62Nlk2KM7:TR?=	M4rMSXNCVkeHUh?=
NCI-H1666	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrONmxRUUN3ME20Nk41PDh6IN88US=>	MXfTRW5ITVJ?
IST-MES1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXoTWM2OD12Nj60NVk3KM7:TR?=	M{XvOnNCVkeHUh?=
SW1116	NGjUc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn64TWM2OD12OD6xO\|U3KM7:TR?=	MVHTRW5ITVJ?
MZ2-MEL	M3fFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLaTWM2OD12OD61NFI3KM7:TR?=	MlfRV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChk1 / Chk1 / Wee1 / p21 / p53 ; PubMed: 29963769 Cancer Med Immunoblotting analysis of CAL39 and SW954 cells showing increase in CHK1 phosphorylation after exposure to AZD7762 for 24 hours. β‐actin is used as loading control. Representative data from n = 3 experiments.	29963769
Growth inhibition assay	Cell viability; PubMed: 23715154 Cancer Discov Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with GraphPad.	23715154

In vivo

AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Chk1 Kinase Assay: Recombinant human Chk1 is expressed as a glutathione S-transferase fusion in insect cells using a baculovirus vector and purified by glutathione affinity chromatography. A synthetic peptide substrate (N-biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR) for Chk1 is synthesized. Final assay concentrations of peptide and ATP (cold + 40 nCi [³³P]ATP) are 0.8 and 1 μM, respectively. Different concentrations of AZD7762, buffer containing peptide and chk1 kinase and ATP, are added sequentially to a 384-well assay plate. The plate is incubated for 2 hours, reaction is stopped by the addition of buffer containing EDTA and scintillation proximity assay beads, and plates are read using a TopCount reader. Data analysis is carried out to determinate a dose response (IC50).
Cell Research:^[1]	- Collapse Cell lines: HT29, SW620 and MDA-MB-231 cells Concentrations: Dissolved in DMSO, final concentration ~12.5 μM Incubation Time: 20 or 48 hours Method: For the checkpoint abrogation assay, HT29 cells are treated for 2 hours with camptothecin (topoisomerase I inhibitor; 0.07 μg/mL) to induce the G2 checkpoint. Cells are then treated for 20 hours with a 12-point titration of AZD7762 (12.5 μM to 6 nM) plus nocodazole. Cells are fixed with 3.7% formaldehyde for 1 hour, permeabilized with PBS containing 0.05% Triton X, and incubated with anti-phH3 antibody for 1 hour followed by Alexa Fluor 488 anti-rabbit and Hoechst stain for 1 hour. Mitotic index is determined on the ArrayScan and expressed as the percentage of cells undergoing mitosis. For the potentiation assays, SW620 or MDA-MB-231 cells are dosed for 24 hours with a 9-point titration of gemcitabine ranging from 0.01 to 100 nM with a constant dose of AZD7762 (300 nM). After 24 hours, medium is removed and AZD7762 alone is added back to the wells for an additional 24 hours. Cells are then incubated in AZD7762-free medium for an additional 72 hours. The effect on cell proliferation is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Male NCr mice implanted s.c. with H460-DNp53 cells or SW620, and male rnu rats implanted s.c. with H460-DNp53 cells Dosages: ~25 mg/kg Administration: Injection i.v. (Only for Reference)

References

[1] Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.

Solubility (25°C)

In vitro	DMSO	50 mg/mL (137.96 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD7762 SDF

Molecular Weight	362.42
Formula	C₁₇H₁₉FN₄O₂S
CAS No.	860352-01-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CC(CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I want to use the inhibitor for i.p. injection, can I use DMSO to dissolve it?
Answer:
Since DMSO has low toxicity with i.p. injection, hydroxyproplyl-β-cyclodextrin is consider a safer co-solvent in compound formulation. In a previous literature report, 11.3% hydroxyproplyl-β-cyclodextrin was used to formulate this compound for i.v. injection.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Selective CHK Inhibitor

MK-8776 (SCH 900776) : Chk1-selective, IC50=3 nM.
Most Potent CHK Inhibitor

CHIR-124 : Chk1, IC50=0.3 nM.
CHK Inhibitor in Clinical Trial

MK-8776 (SCH 900776) : Phase II for Relapsed Acute Myeloid Leukemia.
Classic CHK Inhibitor

PF-477736 : Selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes.

Related Chk Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Rabusertib (LY2603618)

Rabusertib (LY2603618, IC-83) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosis in AML cell lines.
CHIR-124

CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
PF-477736

PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Features:First orally available inhibitor of Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762